EA201690942A1 - Антитела к ccl17 - Google Patents

Антитела к ccl17

Info

Publication number
EA201690942A1
EA201690942A1 EA201690942A EA201690942A EA201690942A1 EA 201690942 A1 EA201690942 A1 EA 201690942A1 EA 201690942 A EA201690942 A EA 201690942A EA 201690942 A EA201690942 A EA 201690942A EA 201690942 A1 EA201690942 A1 EA 201690942A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
ccl17
fragments
products
producing
Prior art date
Application number
EA201690942A
Other languages
English (en)
Other versions
EA034655B1 (ru
Inventor
Кен Боукай
Альфред Дель Векчио
Джон Кихо
Эйлин Лэйси
Линн Мюррей
Мэри Райан
Сандра Сантулли-Маротто
Джон Уилер
Брайан Уайтэйкер
Алексей Тепляков
Original Assignee
Янссен Байотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Байотек, Инк. filed Critical Янссен Байотек, Инк.
Publication of EA201690942A1 publication Critical patent/EA201690942A1/ru
Publication of EA034655B1 publication Critical patent/EA034655B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Настоящее изобретение относится к антителам, специфически связывающимся с CCL17, полинуклеотидам, кодирующим антитела или фрагменты, а также к способам получения и применения указанных продуктов.
EA201690942A 2013-11-06 2014-11-06 Антитела к ccl17 EA034655B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900596P 2013-11-06 2013-11-06
PCT/US2014/064302 WO2015069865A1 (en) 2013-11-06 2014-11-06 Anti-ccl17 antibodies

Publications (2)

Publication Number Publication Date
EA201690942A1 true EA201690942A1 (ru) 2016-09-30
EA034655B1 EA034655B1 (ru) 2020-03-03

Family

ID=53007215

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690942A EA034655B1 (ru) 2013-11-06 2014-11-06 Антитела к ccl17

Country Status (32)

Country Link
US (4) US9944697B2 (ru)
EP (2) EP3466445A1 (ru)
JP (1) JP6556742B2 (ru)
KR (1) KR102331054B1 (ru)
CN (1) CN105722531B (ru)
AU (1) AU2014346770B2 (ru)
BR (1) BR112016010071A2 (ru)
CA (1) CA2929166C (ru)
CL (1) CL2016001081A1 (ru)
CR (1) CR20160187A (ru)
CY (1) CY1124445T1 (ru)
DK (1) DK3065774T3 (ru)
DO (1) DOP2016000105A (ru)
EA (1) EA034655B1 (ru)
ES (1) ES2884255T3 (ru)
HR (1) HRP20211234T1 (ru)
HU (1) HUE058272T2 (ru)
IL (1) IL245488B (ru)
LT (1) LT3065774T (ru)
MA (1) MA39090B2 (ru)
MX (1) MX2016005982A (ru)
MY (1) MY192757A (ru)
NZ (2) NZ758354A (ru)
PE (1) PE20160856A1 (ru)
PH (1) PH12016500826B1 (ru)
PL (1) PL3065774T3 (ru)
PT (1) PT3065774T (ru)
RS (1) RS62373B1 (ru)
SG (1) SG11201603231XA (ru)
SI (1) SI3065774T1 (ru)
UA (1) UA119973C2 (ru)
WO (1) WO2015069865A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058272T2 (hu) * 2013-11-06 2022-07-28 Janssen Biotech Inc Anti-CCL17 antitestek
WO2017065203A1 (ja) * 2015-10-14 2017-04-20 日本全薬工業株式会社 イヌアトピー性皮膚炎の治療及び診断のために用いる抗イヌｔａｒｃ抗体
WO2017079369A2 (en) * 2015-11-03 2017-05-11 Glaxosmithkline Llc Novel antibodies
US20170145086A1 (en) * 2015-11-25 2017-05-25 Visterra, Inc. Antibody molecules to april and uses thereof
CN108250290B (zh) 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 Ccr4的n端重组蛋白及其用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US226A (en) 1837-06-03 Samuel goss
US7709A (en) 1850-10-08 Chas S Gaylord Improved spring-grapple
US4683985A (en) 1985-01-04 1987-08-04 Dresser Industries, Inc. Lubrication system for a vertical gear unit
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
AU2246597A (en) 1996-02-12 1997-08-28 Schering Corporation Mammalian dendritic cell chemokine reagents
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2002006633A1 (en) 2000-07-18 2002-01-24 The Charles Machine Works, Inc. Remote control for a drilling machine
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
MXPA03004793A (es) 2000-11-30 2004-12-03 Medarex Inc Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
WO2004111233A1 (ja) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
EP1870459B1 (en) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US9212230B2 (en) 2007-03-29 2015-12-15 Genmab A/S Bispecific antibodies and methods for production thereof
JP4341704B2 (ja) 2007-07-12 2009-10-07 トヨタ自動車株式会社 ハイブリッド車両およびハイブリッド車両の制御方法
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
AU2009228158B2 (en) * 2008-03-27 2014-02-27 Zymogenetics, Inc. Compositions and methods for inhibiting PDGFRbeta and VEGF-A
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
AU2010315101B2 (en) 2009-11-04 2016-01-28 Fabrus Llc Methods for affinity maturation-based antibody optimization
KR101791430B1 (ko) 2009-11-30 2017-10-30 얀센 바이오테크 인코포레이티드 이펙터 기능이 제거된 항체 Ｆｃ 돌연변이체
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
RU2013110874A (ru) * 2010-08-25 2014-09-27 Ф.Хоффманн-Ля Рош Аг Антитела против il-18r1 и их применения
US9012602B2 (en) * 2010-09-27 2015-04-21 Janssen Biotech, Inc. Macaca fascicularis CCL17
US8394378B2 (en) 2010-09-27 2013-03-12 Janssen Biotech, Inc. Antibodies binding human collagen II
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
SI2644698T1 (en) * 2010-11-17 2018-05-31 Chugai Seiyaku Kabushiki Kaisha MULTISPECIFIC ANTIGEN-TUBULAR MOLECULAR, WITH AN ALTERNATIVE FUNCTION TO THE FACTOR OF BLOOD VIOLATION VIII
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20130171659A1 (en) * 2011-12-28 2013-07-04 Abbott Japan Co., Ltd. Methods of prognosis and diagnosis of rheumatoid arthritis
HUE058272T2 (hu) * 2013-11-06 2022-07-28 Janssen Biotech Inc Anti-CCL17 antitestek

Also Published As

Publication number Publication date
EP3065774B1 (en) 2021-05-26
KR102331054B1 (ko) 2021-11-24
US20180171007A1 (en) 2018-06-21
US20220348647A1 (en) 2022-11-03
US20210017267A1 (en) 2021-01-21
PH12016500826A1 (en) 2016-06-13
IL245488A0 (en) 2016-06-30
LT3065774T (lt) 2021-09-10
MA39090B2 (fr) 2021-10-29
CA2929166A1 (en) 2015-05-14
NZ719506A (en) 2022-09-30
PE20160856A1 (es) 2016-09-03
CA2929166C (en) 2023-08-22
EA034655B1 (ru) 2020-03-03
AU2014346770B2 (en) 2020-05-21
MX2016005982A (es) 2016-08-11
EP3466445A1 (en) 2019-04-10
SI3065774T1 (sl) 2021-11-30
SG11201603231XA (en) 2016-05-30
MA39090A1 (fr) 2018-03-30
PT3065774T (pt) 2021-08-31
JP6556742B2 (ja) 2019-08-07
CL2016001081A1 (es) 2016-10-21
US9944697B2 (en) 2018-04-17
US20150125458A1 (en) 2015-05-07
EP3065774A1 (en) 2016-09-14
US11414484B2 (en) 2022-08-16
UA119973C2 (uk) 2019-09-10
KR20160077198A (ko) 2016-07-01
HUE058272T2 (hu) 2022-07-28
CN105722531A (zh) 2016-06-29
MY192757A (en) 2022-09-07
US10829549B2 (en) 2020-11-10
PL3065774T3 (pl) 2021-12-13
EP3065774A4 (en) 2017-06-21
PH12016500826B1 (en) 2016-06-13
DK3065774T3 (da) 2021-08-23
IL245488B (en) 2020-03-31
JP2016537024A (ja) 2016-12-01
CR20160187A (es) 2016-08-04
WO2015069865A1 (en) 2015-05-14
DOP2016000105A (es) 2016-10-31
HRP20211234T1 (hr) 2021-11-26
RS62373B1 (sr) 2021-10-29
BR112016010071A2 (pt) 2017-12-05
CY1124445T1 (el) 2022-07-22
NZ758354A (en) 2022-09-30
ES2884255T3 (es) 2021-12-10
CN105722531B (zh) 2020-03-06

Similar Documents

Publication Publication Date Title
EA201891093A1 (ru) Антитела, специфически связывающие pd-1, и их применение
EA201491996A1 (ru) Антагонисты st2l и способы их применения
PH12017502180A1 (en) Tau-binding antibodies
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA201492101A1 (ru) Антитела против fcrn
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
PH12017502207A1 (en) Tau-binding antibodies
EA201890434A1 (ru) Антитела к cd154 и способы их применения
PH12015501687A1 (en) Novel binding proteins from pcsk9
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
CY1124445T1 (el) Αντισωματα αντι-ccl17
PL3200822T3 (pl) Cząsteczki wiążące, zwłaszcza przeciwciała, które wiążą się z l1cam (cd171)
EA201690992A1 (ru) Антитела, специфичные к fcrn
EA201591380A1 (ru) АНТАГОНИСТЫ Kv1.3 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201790057A1 (ru) Антитела-антагонисты к интерферону альфа и интерферону омега
EA201591720A1 (ru) Белки, специфические по отношению к baff и b7rp1, и их применение
MX2017007747A (es) Anticuerpos para il-17c.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG TM